

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
February 10, 2022

**DRAFT MEETING ROSTER**

---

---

**ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)**

**LaToya Bonner, PharmD**

Division of Advisory Committee and Consultant Management  
Office of Executive Programs, CDER, FDA

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)**

**Ranjana H. Advani, MD**

Physician Leader, the Lymphoma Clinical Care  
Program  
Saul A. Rosenberg Professor of Lymphoma  
Stanford University Medical Center  
Stanford, California

**Mark R. Conaway, PhD**

Professor and Director of Translational Research  
Division of Translational Research and Applied  
Statistics  
Department of Public Health Sciences  
University of Virginia  
Charlottesville, Virginia

**Massimo Cristofanilli, MD, FACP**

Chief of Breast Medical Oncology  
Associate Director of Precision Medicine  
Meyer Cancer Center (MCC)  
Scientific Director of the Englander Institute of  
Precision Medicine (EIPM)  
Weill Cornell Medicine  
Division of Hematology-Oncology  
New York, New York

**Jorge A. Garcia, MD, FACP**

Chair, Division of Solid Tumor Oncology  
George and Edith Richman Distinguished Scientist  
Chair  
Director, GU Oncology Program  
University Hospitals Seidman Cancer Center  
Case Comprehensive Cancer Center  
Case Western Reserve University  
Cleveland, Ohio

**Pamela L. Kunz, MD**

*(Acting Chairperson)*  
Associate Professor  
Department of Medicine, Division of Oncology  
Yale University School of Medicine  
Director, Center for Gastrointestinal Cancers at  
Smilow Cancer Hospital and Yale Cancer Center  
New Haven, Connecticut

**Christopher H. Lieu, MD**

Associate Professor of Medicine  
Associate Director for Clinical Research  
Director, Gastrointestinal Medical Oncology Program  
University of Colorado  
Aurora, Colorado

**Ravi A. Madan, MD**

Clinical Director  
Genitourinary Malignancies Branch  
Center for Cancer Research  
National Cancer Institute  
National Institutes of Health  
Bethesda, Maryland

**David E. Mitchell**

*(Consumer Representative)*  
Founder, Patients for Affordable Drugs  
Bethesda, Maryland

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
February 10, 2022

**DRAFT MEETING ROSTER (cont.)**

---

---

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting) cont.**

**Jorge J. Nieva, MD**

Associate Professor of Clinical Medicine  
Section Head, Solid Tumors  
University of Southern California (USC) Norris  
Comprehensive Cancer Center  
Keck School of Medicine of USC  
Los Angeles, California

**Ashley Rosko, MD**

Associate Professor  
Division of Hematology  
Department of Internal Medicine  
Medical Director, Oncogeriatric Program  
James Comprehensive Cancer Center  
The Ohio State University  
Columbus, Ohio

**Anthony D. Sung, MD**

Associate Professor of Medicine  
Duke University School of Medicine  
Duke Adult Blood and Marrow Transplant Clinic  
Durham, North Carolina

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)**

**Jonathan D. Cheng, MD**

*(Industry Representative)*  
Senior Vice President  
Head of Oncology Development  
Global Drug Development  
Bristol-Myers Squibb  
Lawrenceville, New Jersey

**TEMPORARY MEMBERS (Voting)**

**Karen E. Arscott, DO, MSc**

*(Patient Representative)*  
Jermyn, Pennsylvania

**Ibiayi Dagogo-Jack, MD**

Assistant Professor of Medicine  
Harvard Medical School  
Massachusetts General Hospital  
Boston, Massachusetts

**John Deeken, MD**

President, Inova Schar Cancer Institute  
Senior Vice President, Inova Health System  
Professor of Medicine, University of Virginia  
Fairfax, Virginia

**Antoinette J. Wozniak, MD**

Professor of Medicine  
Division of Hematology/Oncology  
Department of Medicine  
University of Pittsburgh  
Associate Director for Clinical Research  
Leader, Lung Cancer Disease Center  
UPMC Hillman Cancer Center  
Pittsburgh, Pennsylvania

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
February 10, 2022

**DRAFT MEETING ROSTER (cont.)**

---

---

**FDA PARTICIPANTS (Non-Voting)**

**Richard Pazdur, MD**

Director, Oncology Center of Excellence (OCE)  
Director (Acting)  
Office of Oncologic Diseases (OOD)  
Office of New Drugs (OND), CDER, FDA

**Julia Beaver, MD**

Chief of Medical Oncology, OCE  
Deputy Director (Acting), OOD  
OND, CDER, FDA

**Harpreet Singh, MD**

Director  
Division of Oncology 2 (DO2)  
OOD, OND, CDER, FDA

**Paz Vellanki, MD, PhD**

Medical Officer  
DO2, OOD, OND, CDER, FDA

**Nicole Drezner, MD**

Clinical Team Lead  
DO2, OOD, OND, CDER, FDA